Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab Combined with Idelalisib or Venetoclax in R/R CLL/SLL
NCT02639910Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of tafasitamab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by MorphoSys AG. Started Nov 2016; status: completed.
02
Drugs
tafasitamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02639910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639910.